跳至主要内容
临床试验/JPRN-UMIN000009376
JPRN-UMIN000009376招募中未知

Multi-center, Prospective, Non-interventional, Observational Cohort Study to Investigate Effectiveness and Safety of Rivaroxaban on Prevention of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation in Japanese Clinical Practice - EXPAND study

Tohoku University School of Medicine0 个研究点目标入组 7,000 人开始时间: 2012年11月21日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
7,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • The following patients in whom rivaroxaban is contraindicated for use - Patients with a history of allergies to the ingredients contained in this drug - Patients having a hemorrhagic event (intracranial hemorrhage, gastrointestinal hemorrhage or other clinically significant hemorrhagic events) - Patients having liver disease complicated with coagulation disorder or those having moderate or worse liver disorder (Grade B or C in accordance with the Child-Pugh classification) - Patients having renal failure (creatinine clearance: <15 mL/min) - Women who are or are likely to be pregnant - Patients who are treated with HIV protease inhibitors (including ritonavir, atazanavir and indinavir) - Patients who are treated with oral or injectable formulations of azole antifungal drugs (including itraconazole, voriconazole and ketoconazole (excluding fluconazole))

研究者

相似试验